Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

iShares MSCI United Kingdom (FTSE)Trade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI United Kingdom (FTSE) vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.28, while Neurocrine Biosciences Inc trades at $157.49 (market cap $16.46B). The key difference: iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.

EWUNBIX
Sector
Broad Market / FactorHealth
52-Week High
$48.68$185.50
52-Week Low
$40.90$123.10
Market Cap
$16.46B
Enterprise Value
$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, trades at $48.64, up 0.7% with strong bullish technical signals from moving averages. The ETF shows mixed institutional activity with recent purchases by Balefire LLC and Fifth Third Bancorp offset by Bank of America trimming its position. UK market sentiment remains influenced by Middle East tensions, oil price volatility, and new political leadership under Prime Minister Andy Burnham.

The ETF's outlook balances UK economic resilience against geopolitical risks. Investment opportunity lies in exposure to FTSE 100 companies amid potential economic stabilization, while risks include ongoing Middle East tensions affecting energy markets and uncertainty around new UK fiscal policies under the Burnham administration.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX